VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
ENGN holding history
enGene Therapeutics Inc. in every 13F filed by VR Adviser, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ENGN overviewAll 13F holders of ENGNFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q1 2024
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −4,771,414−100.0% | Sold out | Holders |
| Q1 2026 | 4,771,414 | $32.5M | 1.2% | 00.0% | Unchanged | Holders |
| Q4 2025 | 4,771,414 | $43.1M | 2.1% | −275,000−5.4% | Reduced | Holders |
| Q3 2025 | 5,046,414 | $34.5M | 1.9% | 00.0% | Unchanged | Holders |
| Q2 2025 | 5,046,414 | $18.4M | 1.4% | 00.0% | Unchanged | Holders |
| Q1 2025 | 5,046,414 | $22.6M | 1.9% | 00.0% | Unchanged | Holders |
| Q4 2024 | 5,046,414 | $33.6M | 2.3% | +1,480,573+41.5% | Added | Holders |
| Q3 2024 | 3,565,841 | $23.5M | 1.2% | +739,858+26.2% | Added | Holders |
| Q2 2024 | 2,825,983 | $26.6M | 1.7% | +260,142+10.1% | Added | Holders |
| Q1 2024 | 2,565,841 | $43.5M | 2.1% | +2,565,841 | New | Holders |